Literature DB >> 34998526

[New drug approval: Pembrolizumab in association with chemotherapy as first line treatment for advanced/metastatic oesophageal carcinomas or HERnegative gastroesophageal adenocarcinoma, expressing PD-L1 with a CPS≥10].

Stanislas Quesada1, Pauline Vaflard2.   

Abstract

Entities:  

Keywords:  Adénocarcinome de l’œsophage; Carcinome épidermoïde de l’œsophage; Immunotherapy; Immunothérapie; Oesophageal adenocarcinoma; Pembrolizumab; Squamous cell carcinoma

Mesh：

Substances：

Year:  2022        PMID： 34998526     DOI： 10.1016/j.bulcan.2021.09.021

Source DB:  PubMed          Journal:  Bull Cancer        ISSN： 0007-4551            Impact factor:   1.276


× No keyword cloud information.
  1 in total

1.  High CHAF1A Expression Levels Are Positively-Correlated with PD-L1 Expression and Indicate Poor Prognosis in Gastric Cancer.

Authors:  Zhehan Bao; Yanqiang Zhang; Pengcheng Yu; Yi Wang; Can Hu; Yuhang Xia; Li Yuan; Zhiyuan Xu; Xiangdong Cheng
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-19       Impact factor: 2.650
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.